Consistent with its role as the largest biomedical cluster in Japan and the innovation arm of the City of Kobe, Kobe Biomedical Innovation Cluster (KBIC) has developed a thriving biomedical ecosystem that provides the necessary support for startup’s commercialization on a “seeds to needs” concept for startups generated by collaboration among collaborative ties in the business, academic, governmental and healthcare sectors.» Benefits of KBIC

To date, KBIC’s successful formula has generated numerous startups, which now comprise more than 10% of all of KBIC’s member companies.

To facilitate life science startups’ overseas expansion, KBIC has developed a full-support approach for people, goods, and money so that startups can utilize all available resources.

Here are some of the promising startups at KBIC.

• NextGeM Inc.

  Biotech/Medical Device

  Developing the next generative medicine using tissue stem cells and creating a platform where many young, promising and entrepreneurial scientists can unlock the full potential of stem cells

  Funding Round: Series A

  Funding: $5M

  Click for more details
• PROGENICYTE JAPAN CO., LTD. 

  Biotech/Drug discovery

  Commercialization and licensing of regenerative medicine and IT technologies developed at the University of Central Florida, College of Medicine.

  Funding Round: Seed Early

  Funding: $3M

  Click for more details
• CarbGeM Inc.

  Biotech, Medical Device

  Research and development of next-generation medical-related technologies in the field of infectious diseases.

  Funding Round: Seeds

  Funding: $1M (Seed and non-diluted government grant)

  Click for more details
• NATiAS Inc.

  Oligonucleotide Synthesis

  NATiAS Inc. offers extremely high purity oligonucleotides in mg to ton scale at reasonable prices with unique Blockmer-based oligonucleotide synthesis technology.

  Funding Round: Series B2

  Funding: $5〜10M

  Click for more details
• MiCAN Technologies Inc.

  Drug Discovery

  We contribute to infectious disease research and safety evaluation through provision of special blood cells produced using regenerative medicine technology.

  Funding Round: Series A

  Funding: $1.3M

  Click for more details